Neurological manifestations of antiphospholipid antibody syndrome

Lupus

Volumn 7, Issue SUPPL. 2, 1998, Pages

  Brey, R L ^a   Escalante, A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anti 2 glycoprotein 1; Anticardiolipin antibody; Antiphospholipid syndrome; Chorea; Lupus anticoagulant; Migraine; Seizures; Stroke; Thrombosis; Transverse myelitis; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CHOREA; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DIAGNOSTIC IMAGING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MIGRAINE; MYELITIS; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT ABORTION; SEIZURE; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0031762245     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339800700216     Document Type: Conference Paper

References (84)

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991, 49: 193-280.
2. Inanc M, Radway-Bright EL, Isenberg DA Beta-2-glycoprotein 1 and anti-beta-2-glycoprotein 1 antibodies, where are we now? Br J Rheumatol 1997; 36: 1247-1257.
3. Wahl DG et al Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22
4. Shah NM, Khamashta MA, Atsumi T. Hughes GRV Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998: 7 3-6.
5. Krnic-Barrie S et al A retrospective review of 61 patients with antiphospholipid syndrome Arch Intern Med 1997; 157: 2101-2108
6. Vila P, Hernandez MC, Lopez-Fernandez MF, Baille J Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72. 209-213
7. Drouvalakis KA, Buchanan TTC Phospholipid specificity of auto-immune and drug induced lupus anticoagulants: association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease J Rheumatol 1998; 25: 290-295
8. Labarca JA et al. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review Clin Infec Dis 1997; 24 197-200.
9. Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993, 43: 2069-2073
10. Camerlingo M et al Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995; 92 60-71.
11. Brey RL, Hart RG, Sherman DG, Tegeler CT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-1196.
12. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1190-1196.
13. Levine SR et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome Ann Neurol 1995, 38: 119-124
14. Momalban J et al Value of immunologic testing in stroke patients, a prospective multicenter study. Stroke 1994; 25: 2412-2415
15. Ginsburg KS et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117. 997-1002
16. The Antiphospholipid Antibody in Stroke Study (APASS) Group Anticardiolipin antibodies and the risk of recurrent thrombo-occlusice events and death. Neurology 1997; 48: 91-94.
17. Klemp P et al Anticardiolipin antibodies in ischemic heart disease. Clin Exp Immunol 1988; 89 411-419.
18. Ciocca RG, Choi J, Graham AM. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg 1995, 170: 198-200
19. Del Papa N et al. Endothelial cells as a target for antiphospholipid antibodies role of anti-beta-2-glycoprotein 1 antibodies Am J Reprod Immunol 1997; 38 212-217.
20. Del Papa N et al Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-561
21. Coull BM, Levine SR, Brey RL. The role of antiphospholipid antibodies and stroke. Neural Clin 1992; 10: 125-143
22. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990; 21 1268-1273
23. Ford SE, Lillicrap DM, Brunet D, Ford PM Thrombotic endocarditis and lupus anticoagulant, a pathogenetic possibility for idiopathic rheumatic type valvular heart disease Arch Pathol Lab Med 1989; 113. 350-353
24. Khamashta MA et al. Association of antibodies against phospholipids with valvular heart disease in patients with systemic lupus erythematosus. Lancet 1990, 335: 1541-1544.
25. Nesher G, Ilany J, Rosenmann D, Abraham AS Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features and treatment. Semin Arthritis Rheum 1997; 27: 27-35.
26. Badui E et al. The heart in the primary antiphospholipid syndrome. Arch Med Res 1995; 26: 115-120.
27. Ford SE, Kennedy LA, Ford PM. Clinico-pathological correlations of antiphospholipid antibodies. Arch Pathol Lab Med 1994; 118: 491-495.
28. Levine SR et al. Antiphospholipid antibody associated stroke, prospective assessment of recurrent event risk Stroke 1993; 24: 188.
29. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
30. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipids. JAMA 1988; 259: 550-554.
31. Levine SR et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke 1997, 28 1660-1665.
32. Alarcon-Segovia D et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989, 68: 353-365.
33. Escalante A, Brey RL, Mitchell BD, Dreiner U Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus Am J Med 1995; 98: 559-567
34. Nojima J et al. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997; 96: 447-450.
35. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1995; 26: 160.
36. Sammaritano LR et al Anticardiolipin subclass, association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40: 1998-2006.
37. Vasquez-Mellado J, Llorente L, Richaud-Patin Y, Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of beta-2-glycoprotein 1 and through it that of IgG antiphospholipid antibodies J Autoimmun 1994; 7: 335-348
38. Specker Ch, et al. Cerebral microemboli in patients with antiphospholipid syndrome. Lupus 1997, 6: 638-644.
39. Duhaut P et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Arthritis Rheum 1998; 41: 701-709
40. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies Neurology 1997, 28: 2363-2369.
41. Descheins M-A et al. Coagulations studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis Stroke 1996 27: 1724-1730.
42. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and agaregation Thromb Haemost 1995; 73: 529-534
43. Bokarewa MI et al. Studies on antiphospholipid antibodies. APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 78: 193-200.
44. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994, 3: 247-251.
45. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA Anticardiolipin antibodies in Sneddon's syndrome. Neurology 1990, 40: 464-467.
46. Zelzer B et al Sneddon's syndrome: a long term follow-up of 21 patients. Arch Dermatol 1993, 129: 437-444
47. Tourbah A et al. The natural course of cerebral lesions in Sneddon syndrome Arch Neurol 1997, 54. 53-60.
48. Sneddon IB. Cerebral vascular lesions in livedo reticularis. Br J Dermatol 1965, 77: 180-185.
49. Coull BM et al. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 1987; 18: 1107-1112.
50. Chinnery PF et al Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome J Neurol Neurosurg Psychiatry 1997; 62: 300-301.
51. Schmidt R et al Anticardiolipin antibodies in normal subjects Neuropsychological correlates and MRI findings. Stroke 1995; 26: 749-754.
52. de Moerloose P, Boehlen F, Reber G. Prevalence of anticardiolipin and antinuclear antibodies in an elderly hospitalized population and mortality after a 6-year follow-up Age Ageing 1997; 319-321.
53. Cesbron J-Y, Amouyel Ph, Masy E. Anticardiolipin antibodies and physical disability in the elderly. Ann Intern Med 1997; 126 1003.
54. Schwartz M et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59: 20-23
55. Tietjen GE et al Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events Neurology 1998, 50: 1433-1440.
56. Tietjen GE et al. Factors which predict antiphospholipid immunoreactivity in young people with focal neurologic deficits. Arch Neurol 1993, 50: 833-836.
57. Silvestrini M et al. Migrainous stroke and the antiphospholipid antibodies. Eur Neurol 1994; 34. 316-319.
58. Herranz MT et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37. 586-571
59. Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures Acta Neurol Scand 1989, 79: 114-118.
60. Formiga F, Mitjavila F, Pac M, Moga I Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients Lupus 1997; 6: 486.
61. Liou HH et al. Anticardiolipin antisera from lupus patients with seizures reduce a gaba receptor-medicated chloride current in snail neurons. Life Sci 1994; 54: 1119-1125.
62. Kent M, Vogt E, Rote NS. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system J Rheumatol 1997; 24: 1725-1733.
63. Cervera R et al. Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and recent literature Medicine 1997; 76: 203-212.
64. Asherson RA, Hughes GRV. Antiphospholipid antibodies and chorea. J Rheumatol 1988; 15: 377-379.
65. Hatron PY et al. Chorea, systemic lupus erythematosus, circulating lupus anticoagulants J Rheumatol 1987; 14: 991-993.
66. Furie R, Ishikawa T, Dhawan V, Eidelberg D. Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal metabolism. Neurology 1994, 44: 2197-2199.
67. Sunden-Cullberg J, Tedroff J, Aquilonius S-M. Reversible chorea in primary antiphospholipid syndrome Move Dis 1998; 13: 147-149.
68. Harris EN et al. Lupoid sclerosis: a possible pathogenic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44: 281-283
69. Lavalle C et al. Transverse myelitis: a manifestation of systemic lupus erythematosus associated with antiphospholipid antibodies. J Rheumatol 1990, 17. 34-37.
70. Ruiz-Arguelles GJ, Guzman-Ramos J, Flores-Flores J, Garay-Martinez J. Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus 1998; 7 49-50.
71. Jackson C et al. Anticardiolipin antibodies in Guillain-Barré Syndrome Clin Exp Rheumatol 1992; 10 657
72. Harris EN et al Antiphospholipid antibodies in acute Guillain-Barré syndrome. Lancet 1983; 2: 1361-1362
73. Shigeta H et al Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 1997; 20: 1896-1899.
74. Toubi E et al. Autoimmune aberration in sudden sensorineural hearing loss, association with anticardiolipin antibodies. Lupus 1997; 6: 540-542.
75. Naarendorp M, Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythemaotsus or lupus-like syndromes and antiphospholipid antibodies J Rheumatol 1998; 25: 589-592.
76. Montalban J et al. Transient global amnesia and antiphospholipid antibodies. Clin Exp Rheumatol 1989; 7: 85-87
77. Rafuse PE, Canny CLB. Initial identification of antinuclear antibody-negative systemic lupus erythematosus on ophthalmic examination: a case report with discussion of the ocular significance of anti-cardiolipin (antiphospholipid) antibodies. Can J Ophthalmol 1992; 27: 189-193.
78. Labutta RJ. Ophthalmic manifestations in the antiphospholipid syndrome. In Asherson RA, Cervera R, Piette JC, Shoenfeld Y (eds) The Antiphospholipid Syndrome CRC Press: Boca Raton, FL, 1996, pp 213-218.
79. Molad Y et al. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J Rheumatol 1992, 19 556-561.
80. Provenzale JM et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings. Radiology 1994; 192. 531-537.
81. Toubi E, Khamashta MA, Panarra A, Hughes GRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus Am J Med 1995; 99: 397-401.
82. Sailer M et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus, J Neurol 1997; 244: 186-193.
83. Hachulla E et al. Cerebral magnetic imaging in patients with or without antiphospholipid antibodies. Lupus 1998, 7: 124-131.
84. Brey RL, Levine SR. Treatment of neurologic complications of the antiphospholipid syndrome. Lupus 1996 5: 473-476